Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPIE08
|
|||
| Drug Name |
ASP8731
|
|||
| Synonyms |
ML-0207
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 1 | [1] | |
| Company |
Astelllas
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transcription regulator protein BACH1 (Bach1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05167526) A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP8731 in Healthy Adult Participants, Including an Assessment of a Food Effect. U.S.National Institutes of Health. | |||
| REF 2 | The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell disease. Front Med (Lausanne). 2023 Apr 18;10:1101501. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.